Search research articles
Contact Us
Filters
Showing results (21-30 of 71) with videos related to
Page
of 8
Sort By:
European Journal of Clinical Investigation
|
October 3, 2025
The biology of lipoprotein(a): From genetics to molecular mechanisms
Mark Atallah, Nadim Nasrallah, Tarek Harb, et al.
Cleveland Clinic Journal of Medicine
|
April 3, 2020
In reply: Infective endocarditis: Don't forget the ICE
Nkemdilim Mgbojikwe, Steven R Jones, Thorsten M Leucker, et al.
Annual Review of Pharmacology and Toxicology
|
July 28, 2023
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics
Erfan Tasdighi, Rishav Adhikari, Omar Almaadawy, et al.
Journal of Cardiology Cases
|
December 15, 2015
Idiopathic 'True' Left Ventricular Aneurysm
Thorsten M Leucker, Vineet Agrawal, Hussein Rahim, et al.
European Heart Journal Open
|
September 2, 2024
Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk
Tarek Harb, Efthymios Ziogos, Roger S Blumenthal, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese
|
October 11, 2020
The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives
Michael A Vavuranakis, Steven R Jones, Rhanderson Cardoso, et al.
European Journal of Clinical Investigation
|
June 26, 2024
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition-Part one: Pleiotropic pro-atherosclerotic effects of PCSK9
Alexander M Cao Zhang, Efthymios Ziogos, Tarek Harb, et al.
Journal of Clinical Lipidology
|
January 16, 2026
Tailoring strategies for dyslipidemia management and atherosclerotic cardiovascular disease prevention in muscular dystrophy patients
Jelani K Grant, Pooja Selvam, Margaret Koester, et al.
European Journal of Clinical Investigation
|
June 26, 2024
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition-Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition
Alexander M Cao Zhang, Efthymios Ziogos, Tarek Harb, et al.
Trends in Cardiovascular Medicine
|
April 19, 2021
Coronary heart disease risk: Low-density lipoprotein and beyond
Gabriel E Shaya, Thorsten M Leucker, Steven R Jones, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 71) with videos related to
Sort By:
Page
of 8
European Journal of Clinical Investigation
|
October 3, 2025
The biology of lipoprotein(a): From genetics to molecular mechanisms
Mark Atallah, Nadim Nasrallah, Tarek Harb, et al.
Cleveland Clinic Journal of Medicine
|
April 3, 2020
In reply: Infective endocarditis: Don't forget the ICE
Nkemdilim Mgbojikwe, Steven R Jones, Thorsten M Leucker, et al.
Annual Review of Pharmacology and Toxicology
|
July 28, 2023
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics
Erfan Tasdighi, Rishav Adhikari, Omar Almaadawy, et al.
Journal of Cardiology Cases
|
December 15, 2015
Idiopathic 'True' Left Ventricular Aneurysm
Thorsten M Leucker, Vineet Agrawal, Hussein Rahim, et al.
European Heart Journal Open
|
September 2, 2024
Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk
Tarek Harb, Efthymios Ziogos, Roger S Blumenthal, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese
|
October 11, 2020
The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives
Michael A Vavuranakis, Steven R Jones, Rhanderson Cardoso, et al.
European Journal of Clinical Investigation
|
June 26, 2024
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition-Part one: Pleiotropic pro-atherosclerotic effects of PCSK9
Alexander M Cao Zhang, Efthymios Ziogos, Tarek Harb, et al.
Journal of Clinical Lipidology
|
January 16, 2026
Tailoring strategies for dyslipidemia management and atherosclerotic cardiovascular disease prevention in muscular dystrophy patients
Jelani K Grant, Pooja Selvam, Margaret Koester, et al.
European Journal of Clinical Investigation
|
June 26, 2024
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition-Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition
Alexander M Cao Zhang, Efthymios Ziogos, Tarek Harb, et al.
Trends in Cardiovascular Medicine
|
April 19, 2021
Coronary heart disease risk: Low-density lipoprotein and beyond
Gabriel E Shaya, Thorsten M Leucker, Steven R Jones, et al.
Page
of 8